Showing results (1-10 of 344) with videos related to
Sort By:
Pageof 35
Best Practice & Research. Clinical Endocrinology & Metabolism|December 13, 2006
Pathophysiology of insulin resistanceGiorgio SestiGiornale Italiano Di Cardiologia (2006)|December 22, 2012
[Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients]Giorgio SestiAnnals of Medicine|January 14, 2003
Apoptosis in the beta cells: cause or consequence of insulin secretion defect in diabetes?Giorgio SestiGiornale Italiano Di Cardiologia (2006)|December 14, 2011
[Effects of glucagon-like peptide-1 on appetite and body weight: preclinical and clinical data]Giorgio SestiClinical Therapeutics|January 30, 2010
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitusEduard Montanya, Giorgio SestiGiornale Italiano Di Cardiologia (2006)|April 1, 2016
[Cardiovascular outcome clinical trials in type 2 diabetes mellitus: what are the epidemiological and methodological evidence and the first evaluations to date?]Teresa Vanessa Fiorentino, Giorgio SestiGiornale Italiano Di Cardiologia (2006)|January 28, 2015
[Tight glycemic control in the management of diabetic patients: what has changed since the '90s in the clinical approach?]Teresa Vanessa Fiorentino, Giorgio SestiMolecular Diagnosis & Therapy|September 29, 2012
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic dataGaia Chiara Mannino, Giorgio SestiGiornale Italiano Di Cardiologia (2006)|December 24, 2013
[Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors]Teresa Vanessa Fiorentino, Giorgio SestiEndocrine|November 28, 2015
Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitorsTeresa Vanessa Fiorentino, Giorgio SestiPageof 35